The review, led by Samruddhi Kaknale and Varnitha Manikantan of Symbiosis Medical College for Women in Pune, India, together with collaborators at Symbiosis School of Biological Sciences, Karunya Institute of Technology and Sciences, and Manipal Institute of Technology Bengaluru, systematically maps the pathobiology of infant neuroblastoma, the mechanics of CRISPR/Cas9 targeting, and the nanocarrier platforms that might deliver the editing machinery safely in vivo. The authors are careful to frame the work as an investigational hypothesis rather than an established clinical application, noting that direct evidence in infant neuroblastoma remains limited and that most findings come from general neuroblastoma models, non-cancer models, or adult cancers that should not be interpreted as proof of efficacy in infants.

At the heart of the therapeutic concept lie two molecular hallmarks: MYCN amplification and activating ALK mutations. MYCN is a potent transcription factor that drives proliferation, suppresses apoptosis, and propels tumor progression, and its amplification is an established adverse prognostic feature associated with advanced stage, rapid growth, and poor outcome. ALK mutations, meanwhile, produce constitutive kinase activity that fuels oncogenic signaling. Because these alterations define the biology of high-risk disease, they represent the most attractive targets for precision gene editing, offering a shift from broad cytotoxic chemotherapy toward highly selective molecular intervention.

The CRISPR/Cas9 system itself is elegantly simple in principle. It consists of the Cas9 nuclease and a single guide RNA, a synthetic chimeric RNA containing a scaffold for Cas9 binding and a 20-nucleotide spacer complementary to the target DNA. For the commonly used Streptococcus pyogenes Cas9, target recognition requires a 5′-NGG-3′ protospacer-adjacent motif. Once directed to its genomic address, Cas9 induces a targeted double-strand break that the cell repairs through endogenous mechanisms. The predominant pathway, non-homologous end joining, is error-prone and typically generates small insertions or deletions that frameshift and inactivate the target gene, a powerful strategy for knocking out oncogenes such as MYCN or ALK. The less frequent homology-directed repair pathway uses a homologous DNA template and can, in principle, correct specific point mutations, such as activating ALK variants, with meticulous precision.

Recent advances have refined this toolkit further. Base editors harness a catalytically impaired Cas9 fused to a deaminase to convert single nucleotides directly, for example C to T or A to G, without double-strand breaks. Prime editors combine nCas9 with reverse transcriptase and a prime editing guide RNA to direct templated insertions, deletions, and all twelve possible base-to-base conversions, offering search-and-replace capabilities that reduce the risk of indels and chromosomal rearrangements. The review notes that direct evidence for base or prime editing in neuroblastoma remains limited, marking these approaches as avenues for future investigation rather than validated options.

Preclinical evidence, however, is already compelling in cell lines and animal models. High-throughput CRISPR screens have identified genetic dependencies in neuroblastoma, including a reliance on the PRC2 components EZH2, EED, and SUZ12 in MYCN-amplified models. Direct knockout of MYCN and ALK in various neuroblastoma cell lines has produced significant reductions in cell proliferation, inhibition of tumor growth in vitro and in vivo, and induction of apoptosis. CRISPR interference targeting the MYCN promoter has effectively repressed MYCN expression and suppressed neuroblastoma cell growth, while knockout of uPAR, a gene linked to cellular invasion, has inhibited invasive phenotypes, suggesting the technology can also blunt metastasis by targeting genes involved in tumor cell motility.

Yet the review is unflinching about the obstacles. Delivering Cas9 and its guide RNA into a sufficient percentage of tumor cells in vivo remains the central challenge, complicated by the large size, negative charge, immunogenicity, and degradation susceptibility of CRISPR cargoes. The Cas9 protein, derived from bacteria, can elicit innate and adaptive immune responses that clear edited cells or render subsequent treatments unproductive, and preexisting adaptive immunity to Cas9 proteins has been identified in humans. Off-target editing persists despite improvements in guide RNA design and high-fidelity Cas9 variants, and achieving uniform editing efficiency across a heterogeneous solid tumor microenvironment, with poor penetration and variable cellular uptake, is extraordinarily difficult. For infants, whose expected lifespans stretch across decades, persistent Cas9 activity, potential germline exposure, chromosomal rearrangements, large deletions, structural variants, and long-term effects in normal tissues demand careful assessment and lifelong follow-up before any clinical translation.

Nanoparticle delivery systems emerge as the leading candidates to surmount these barriers. Lipid nanoparticles, the most clinically advanced platform and the technology behind successful mRNA vaccines, typically comprise ionizable lipids, helper lipids like cholesterol and phospholipids, and PEGylated lipids. Ionizable lipids are positively charged at acidic pH but neutral at physiological pH, facilitating nucleic acid complexing and endosomal escape after cellular uptake, while PEGylated lipids preserve systemic circulation by preventing rapid elimination by the reticuloendothelial system. Delivery of Cas9 mRNA with sgRNA allows transient protein expression, minimizing off-target effects and immune activation associated with prolonged Cas9 activity, whereas pre-formed Cas9 ribonucleoproteins offer reduced immunogenicity and faster editing onset but are more complicated to encapsulate due to their size.

Polymeric and inorganic nanocarriers expand the design space. Biodegradable polymers such as PLGA, PEG, chitosan, and dendrimers can encapsulate CRISPR components with adjustable degradation and sustained release, and PLGA’s capacity to safeguard sensitive payloads makes it widely used for surface functionalisation aimed at neuroblastoma cell targeting. Gold nanoparticles are biocompatible and easily functionalized for direct conjugation with Cas9 and sgRNA, with photothermal applications, while magnetic nanoparticles enable magnetic targeting and MRI tracking, and mesoporous silica nanoparticles provide high loading, controlled release, and rigid protection of CRISPR cargo. For the minority of patients with CNS involvement or relapse, blood-brain barrier penetration strategies, including receptor-mediated transcytosis via ligands binding the transferrin, insulin, or low-density lipoprotein receptors, cell-penetrating peptides like TAT and R8, and focused ultrasound combined with microbubbles to transiently and locally disrupt the barrier, are being explored, though the review cautions that enhanced permeability does not necessarily indicate efficient nanoparticle delivery to the brain and may increase the risk of unintended CNS exposure and neurotoxicity.

The authors conclude that robust preclinical validation in relevant in vitro and in vivo models, including organoids, patient-derived xenografts, and orthotopic systems that precisely mimic the human disease, is essential for determining efficacy, characterizing biodistribution, evaluating off-target effects, and establishing a preliminary safety profile. Ethical and regulatory considerations add further complexity, as infants lack capacity for informed consent, requiring parents or legal guardians to decide in the child’s best interests amid the potentially irreversible nature of genomic modification. Future work should prioritize more selective nanoparticles, gene-editing tools with high precision and minimal off-target effects, and internationally harmonised regulatory frameworks for paediatric applications. With sustained interdisciplinary collaboration, the convergence of nanoparticle delivery and CRISPR/Cas9 precision may ultimately enable safer and more effective therapies for infants with neuroblastoma, though the review emphasizes that current evidence remains predominantly preclinical and is not yet sufficient to establish the optimal nanoparticle or CRISPR technique for infant neuroblastoma.

Subject of Research: Nanoparticle-enabled CRISPR/Cas9 gene editing as a potential therapy for infant neuroblastoma

Article Title: Precision gene editing in infant neuroblastoma: a review of nanoparticle: enabled CRISPR/Cas9 therapies

Article References: Kaknale, S., Ranjan, A., Enoch, I. V. M. V., Vyas, A., & Manikantan, V. (2026). Precision gene editing in infant neuroblastoma: a review of nanoparticle: enabled CRISPR/Cas9 therapies. Molecular Biology Reports, 53(1), Article 1725. https://doi.org/10.1007/s11033-026-12916-2

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12916-2

Keywords: infant neuroblastoma, CRISPR/Cas9, nanoparticles, lipid nanoparticles, gene therapy, MYCN, ALK, drug delivery, paediatric oncology, base editing, prime editing, preclinical models

The core problem PrimeStack addresses is one of the most stubborn bottlenecks in crop biotechnology. Conventional genetic engineering in plants typically relies on Agrobacterium-mediated transformation or particle bombardment, methods that deliver foreign DNA into the genome essentially at random. A transgene may land in the middle of an essential gene, disrupting it, or it may land in a region of heavily silenced heterochromatin, where it remains transcriptionally mute. Even when a favorable insertion occurs, the position effects vary from plant to plant, forcing breeders to screen large populations of transformants to find the rare line in which the introduced trait works as intended. Homologous recombination, the mechanism that would in principle allow precise gene targeting, operates at vanishingly low frequencies in plant cells, and while double-strand break technologies such as CRISPR-Cas9 have boosted targeted insertion, they rely on break-and-repair processes that are inefficient for large cargos and can introduce unwanted collateral damage at the cut site.

PrimeStack takes a fundamentally different route: it avoids double-strand breaks altogether. The platform fuses two molecular machines with complementary talents. The first is prime editing, a CRISPR-derived technique that uses a modified Cas9 protein fused to a reverse transcriptase to write new genetic information into a genome without cutting both DNA strands. Prime editors are superb at installing small, precise sequence changes, but they cannot paste in kilobases of DNA. The second component is Bxb1, a large serine recombinase, an enzyme that catalyzes recombination between two specific DNA sequences called attP and attB. Bxb1 is unidirectional, meaning that once it has joined an attP site to an attB site, the reaction is effectively irreversible under cellular conditions, locking the integrated DNA in place.

The logic of the system unfolds in two stages. In the first stage, optimized prime editors are used to install a short attP landing pad, the recognition sequence for Bxb1, at a predefined genomic safe harbor in rice. These safe harbors are genomic addresses that the team experimentally confirmed to tolerate foreign DNA without harming the plant, positions where an inserted cassette can be expressed reliably and stably across generations. The prime editing step achieves high fidelity and, critically, the installed landing sites are heritable, meaning they can be passed through seeds to establish editor-free recipient lines. In the second stage, the Bxb1 integrase recognizes the attP site and catalyzes recombination with an attB site carried on the donor cargo, driving the entire multigene payload into the genome in a single, directional, irreversible event.

What makes the achievement remarkable is the size and complexity of the cargos involved. The team showed that PrimeStack can integrate multikilobase payloads containing multiple genes, the kind of genetic freight that conventional gene targeting almost never manages in plants. This capability matters because many of the traits breeders most want to engineer are not single-gene traits. Nutritional enhancement, disease resistance, drought tolerance and nitrogen-use efficiency often require coordinated expression of several genes, sometimes entire biosynthetic pathways. The demonstration case in the study is a carotenoid cassette: the researchers targeted the insertion of a multigene pathway for carotenoid production, the pigments behind the vitamin A content of Golden Rice, into a validated safe harbor, showing that the platform can build a functional metabolic pathway at a chosen genomic address.

The efficiency numbers are the headline statistic. Junction-specific PCR analyses, which verify that the DNA has been joined correctly at both ends of the insertion, confirmed targeted large-cargo integration in regenerated rice plants at rates of up to 45 percent. In practical terms, this means that nearly half of the plants recovered from a transformation experiment carried the cargo at the intended site, a dramatic improvement over the near-zero efficiencies of spontaneous gene targeting. Equally important for agricultural deployment, the researchers observed no obvious morphological differences between the edited plants and wild-type controls at five weeks after transfer to soil under the evaluated conditions, an early indication that the editing process and the insertion site do not impose a developmental penalty.

The modular architecture of PrimeStack is what elevates it from a clever demonstration to a general-purpose platform. Because the prime editing step and the integrase step are separable, breeders can first generate and characterize landing-pad lines, confirming that the attP site is correctly installed and that plants carrying it are healthy and fertile. Those lines then become standardized recipients into which any attB-flanked cargo can be stacked, one after another, at the same genomic address. This opens the door to trait pyramiding, the accumulation of multiple desirable traits in a single elite variety, done predictably rather than through years of crossing and selection. It also enables pathway construction, the stepwise assembly of synthetic metabolic routes in plants, with each new module landing at a known position next to the previous ones.

The implications extend well beyond the rice paddy. The authors position PrimeStack as a chassis for plant synthetic biology and scalable plant-based biomanufacturing. Plants are already exploited as production platforms for pharmaceuticals, industrial enzymes and specialty chemicals, but the randomness of conventional transformation has made product quality variable and regulatory approval cumbersome, since every independent insertion event must be characterized individually. A platform that deposits cargos at the same safe harbor in every line produces materials with consistent expression profiles, simplifying both manufacturing and the regulatory dossier. The same predictability benefits basic research, allowing scientists to compare different gene constructs at an identical genomic context, eliminating the position-effect noise that has long confounded such comparisons.

There are, of course, hurdles between a rice proof-of-concept and routine deployment across crops. Prime editing efficiencies vary with target site and species, and the system requires delivering both the prime editor machinery and the integrase with its donor cargo into plant cells, a logistics challenge that transformation technology must continue to address. The 45 percent figure represents an optimized condition, and performance across other crop species, other safe harbors and even larger cargos remains to be established. Yet the direction of travel is unmistakable. By marrying the write-precision of prime editing with the irreversible joining power of a large serine integrase, PrimeStack transforms the plant genome from a target of semi-random bombardment into a programmable substrate, one landing pad at a time. If the platform transfers as cleanly to maize, wheat and other staples as the underlying logic suggests it might, the era of predictable, site-specific gene stacking in crops may have just begun.

Subject of Research: Site-specific integration of large multigene DNA cargos into plant genomes using combined prime editing and serine integrase technology in rice

Article Title: PrimeStack editors enable efficient and site-specific integration of large multigene cargos in plants

Article References: Sánchez, E., Sedeek, K., Butt, H., & Mahfouz, M. (2026). PrimeStack editors enable efficient and site-specific integration of large multigene cargos in plants. PLOS Biology, 24(10), e3003778. https://doi.org/10.1371/journal.pbio.3003778

Image Credits: AI Generated

DOI: 10.1371/journal.pbio.3003778

Keywords: PrimeStack, prime editing, Bxb1 integrase, rice, genome editing, genomic safe harbor, gene stacking, carotenoid biosynthesis, crop biotechnology, plant synthetic biology, trait pyramiding, PLOS Biology

The target of the engineering campaign was 4-hydroxyphenylpyruvate dioxygenase, or HPPD, an enzyme that sits at a critical junction in plant metabolism. HPPD catalyzes a key step in the tyrosine degradation pathway, converting 4-hydroxyphenylpyruvate into homogentisate, which in turn feeds the production of plastoquinone and tocopherols. Because plastoquinone is indispensable for carotenoid biosynthesis and for protecting the photosynthetic apparatus, blocking HPPD with herbicides such as mesotrione, isoxaflutole and fenpyrazone causes treated plants to bleach and die. This vulnerability makes HPPD inhibitors among the most valuable weed killers in modern agriculture, but it also means that any crop engineered to tolerate them must maintain a delicately balanced enzyme that still performs its metabolic duties while refusing to bind the herbicide.

Previous attempts to generate herbicide-tolerant HPPD variants relied largely on directed evolution, randomly mutating the gene and screening survivors for resistance. That approach can find resistance mutations, but it offers no guarantee that the resulting enzyme retains full catalytic activity, and it typically operates on a single genetic axis: the protein sequence itself. The Gao laboratory chose a fundamentally different route, beginning with structure. The team solved the crystal structure of rice HPPD, OsHPPD, depositing it in the Protein Data Bank under accession 21WF, and used the three-dimensional map of the enzyme to identify amino acid positions where substitutions could plausibly disrupt herbicide binding while leaving the catalytic machinery untouched. This structure-guided design narrowed the search space dramatically, focusing attention on residues near the herbicide-binding pocket rather than across the entire protein.

The structural analysis pointed to a cluster of glycine residues and a phenylalanine at position 378 as prime candidates. The researchers designed a panel of coding variants, including F378A, G414A, G415V and a series of substitutions at position 417, each chosen because the atomic geometry suggested the mutation would either enlarge or reshape the herbicide-binding cavity without disturbing the iron-coordinating active site or the substrate-channeling architecture of the enzyme. Biochemical assays confirmed the logic: the engineered enzymes retained their dioxygenase activity against the natural substrate while showing markedly reduced sensitivity to mesotrione, the HPPD-inhibiting herbicide used as the primary test compound throughout the study.

Installing these mutations in the rice genome required precision rather than brute force. The team deployed prime editing, a CRISPR-derived technology that uses a modified Cas9 fused to a reverse transcriptase and an extended guide RNA carrying the desired edit, to write the designed substitutions directly into the endogenous OsHPPD locus. Prime editing was chosen over conventional CRISPR-Cas9 knockout approaches because it makes exact sequence changes without creating double-strand DNA breaks, avoiding the large deletions, rearrangements and chromosomal damage that have been documented as unintended consequences of break-based editing. Using both standard pegRNA vectors and engineered epegRNA systems, the researchers generated transgene-free rice lines carrying each of the designed resistance alleles, confirming the edits by Sanger sequencing and verifying that the plants grew normally in the absence of herbicide.

The coding mutations alone conferred meaningful tolerance, but the team suspected that a second lever could push resistance to a level that would survive real-world field conditions. Their attention turned to cis-regulatory DNA, the non-coding sequences that govern how strongly a gene is expressed. Drawing on expression-modulating elements, short enhancer-like motifs that can boost transcription when placed near a promoter, the researchers screened candidate sequences in rice protoplasts using a dual-luciferase reporter assay. One sequence stood out: a compact 22-base-pair element, dubbed EME, that significantly increased expression when inserted upstream of the OsHPPD core promoter and 5-prime untranslated region. Computational analysis with the PlantPAN 4.0 database predicted that the element recruits transcription factors capable of amplifying gene activity, and RNA-folding simulations suggested the short sequence adopts a defined secondary structure that may facilitate its integration during prime editing.

The mechanism of EME insertion is itself a technical tour de force. The 22-base-pair element contains a palindromic sequence, meaning it reads the same in both directions, and the researchers showed that during the flap-equilibration step of prime editing this palindrome can exist either as a linear strand, producing a precise replacement, or as a structured three-prime flap whose microhomology with the genomic target allows flexible insertion. By tuning the editing system, including the use of an enhanced prime editor called ePPEplus, the team achieved efficient installation of the EME at the OsHPPD locus in whole plants, generating alleles that combined a resistance mutation in the coding region with an expression-boosting element in the regulatory region, all within a single gene and without any foreign DNA.

The results were striking. Rice plants carrying both layers of engineering, a resistance mutation such as G417A or G414A plus the EME element, showed elevated OsHPPD mRNA and protein abundance and tolerated mesotrione at rates up to four times the recommended field application dose. The plants also withstood isoxaflutole and fenpyrazone, demonstrating that the tolerance extends across the HPPD-inhibitor class rather than being specific to a single chemistry. Crucially, multi-season field trials in Hainan, China, in 2025 and 2026 showed that the engineered lines matched or exceeded wild-type plants in every major agronomic trait measured, including plant height, grain number per panicle, seed-setting rate, thousand-grain weight, tiller number and grain yield per plant. The absence of yield penalties is the detail that separates this work from many earlier trait-engineering efforts, where resistance often came at the cost of vigor.

To test whether the framework was a rice-specific trick or a general principle, the team turned to wheat, a hexaploid crop whose genome carries three homoeologous copies of the HPPD gene, TaHPPD-A1, TaHPPD-B1 and TaHPPD-D1. Multiplex prime editing was used to introduce glycine-to-alanine substitutions at the positions corresponding to rice G414 across all three homoeologs, and a duplicated EME element was then inserted into the regulatory region of one TaHPPD-B1 allele. The resulting wheat plants, designated 2EME-G404A, showed increased TaHPPD transcript and protein levels and enhanced mesotrione tolerance relative to plants carrying only the coding mutation. The demonstration that the dual-layer strategy functions in a polyploid genome, with its added complexity of multiple gene copies and larger regulatory landscapes, is strong evidence that the approach can be ported across species and genome architectures.

Beyond herbicide tolerance, the study articulates a template that the authors argue is broadly applicable to crop improvement. Most engineered traits to date have manipulated either a protein or a regulatory element, and the single-axis approach often hits a ceiling: a resistance enzyme may be too weak, or an overexpressed wild-type enzyme may still be inhibited. By coordinating structure-guided protein design with precise cis-regulatory tuning at the same locus, the dual-layer framework allows each layer to compensate for the limitations of the other, producing alleles that are simultaneously resistant and abundantly expressed. The strategy also sidesteps the transgene silencing, position effects and regulatory burdens associated with inserting foreign genes, because every change is written into the crop’s own DNA. With deep-sequencing data deposited under NCBI BioProject PRJNA1417282 and analysis code released through GitHub, the work provides both the biological blueprint and the computational toolkit for breeding programs seeking to engineer durable, penalty-free traits in the crops that feed the world.

Subject of Research: Dual-layer genome editing of HPPD coding and regulatory sequences to engineer herbicide-tolerant rice and wheat

Article Title: Coordinating structure-guided design and cis-regulatory optimization to engineer elite herbicide-tolerance alleles in crops

Article References: Zhang, R., Chai, Z., Wang, M., Chen, S., Liu, M., Shi, X., Zhang, C., Wang, W., Zhang, F., Wang, G., Lei, G., Chen, Y., & Gao, C. (2026). Coordinating structure-guided design and cis-regulatory optimization to engineer elite herbicide-tolerance alleles in crops. Nature Plants. https://doi.org/10.1038/s41477-026-02423-4

Image Credits: AI Generated

DOI: 10.1038/s41477-026-02423-4

Keywords: genome editing, prime editing, herbicide tolerance, HPPD, rice, wheat, cis-regulatory elements, mesotrione, crop breeding, protein design, CRISPR, plant biotechnology

Jonathan Weissman, an HHMI Investigator based at the Whitehead Institute, and Jay Shendure, an HHMI Investigator at the University of Washington, worked independently on the problem, and each arrived at a solution built on the same audacious idea: instead of trying to watch cells divide, teach the cells to record their own divisions in DNA. The two teams developed distinct but conceptually related recording technologies, applied them to mouse embryos, and read out the accumulated records by sequencing individual cells. The result is a pair of complementary maps that reveal both what each cell became and where it came from, a combination that has never before been available for a mammal at this scale.

The historical benchmark for this kind of work dates to 1983, when researchers completed the lineage of the roundworm Caenorhabditis elegans, charting every single cell division from fertilized egg to adult. That feat was possible only because the roundworm embryo is transparent and develops outside the body, allowing scientists to sit at a microscope and watch each division as it happened. A mouse embryo, by contrast, grows inside its mother, hidden from direct observation, and expands from one cell to hundreds of millions of cells in just a few weeks. No microscope could follow that process, and no conventional measurement could capture it. As Weissman puts it, the new work is proof of principle that what was done with the roundworm in 1983 can now be done for mammals like mice and, by extension, like humans.

Weissman’s team solved the problem with a tool called PEtracer, unveiled in 2025, which relies on a genome-editing method known as prime editing. Prime editing can install precise, small changes into DNA without cutting both strands of the double helix, making it an ideal instrument for writing permanent marks into a genome. PEtracer deploys this capability at more than a hundred sites in the genome. Each time a cell divides, the recording machinery adds new marks, and those marks are inherited by every daughter cell, which then accumulate additional marks of their own. Over the course of development, the genome of each cell becomes a layered archive of its ancestry, with earlier marks shared by all descendants and later marks distinguishing individual branches of the family tree.

Reading the archive is where the power of the approach becomes clear. Because the marks are captured by sequencing individual cells, a single experiment yields two kinds of information at once. The shared mutations reveal the lineage, showing which cells are sisters, cousins, or distant relatives, while the natural gene expression profile of each cell reveals its identity and function. In the new research, Weissman’s team engineered stem cells carrying the PEtracer recording apparatus and injected them into a mouse embryo. As the embryo developed in utero, the heritable marks were incorporated into nearly every cell the embryo produced. By analyzing each cell at the end of development, the researchers assembled massive family trees that connected the final cell types of the mouse back to their common progenitors.

Shendure’s team took a parallel route with a technology called DNA Typewriter, which his group introduced in 2022. DNA Typewriter also uses prime editing, but it records each editing event on a dedicated string of DNA that functions like a ticker tape, logging divisions in sequence as the embryo grows. In the new study, the team injected the components of DNA Typewriter into a fertilized mouse egg, allowing the recording to begin at the very first division of life. As the cells multiplied, the tape accumulated a chronological record of the embryo’s cellular expansion. Reading that tape back allowed the researchers to reconstruct the developmental history of the animal from zygote to late organogenesis, the stage at which the major organs have taken shape.

The two technologies share a common motivation, one that Shendure articulated in explaining why recording is superior to existing approaches. Most biological measurements, he notes, depend either on live imaging, which is limited because most animal tissues are not transparent, or on genomics, which is destructive and captures only a single moment in time. Recording techniques change the equation entirely. By writing history into DNA as it happens, they enable measurements over time in settings that cannot be directly visualized, including the interior of a growing mammalian embryo. The cell divides, each daughter receives a mark, and those marks are inherited and extended through subsequent generations, so that by looking at the marks in the DNA at the end, the relationships among millions of cells can be reconstructed after the fact.

The scientific payoff of these maps is expected to be broad. Understanding how cells differentiate to build tissues is one of the central questions of developmental biology, and the new lineage trees provide a direct view of which progenitors give rise to which mature cell types. The maps also offer a way to study disease at its origins, revealing where and when a developing embryo is most vulnerable to environmental or genetic stressors. In cancer biology, the same recording tools can be turned on tumors to investigate how cancers initiate, grow, spread through the body, and develop resistance to therapies, questions that likewise unfold at moments and in places that researchers cannot observe directly. If the information can be recorded in DNA, Weissman explains, then the underlying processes can be inferred and reconstructed in detail even after they have occurred.

Beyond the immediate biological insights, the data sets generated by the two teams are destined to play a role in computational biology. The researchers plan to use the lineage and cell fate information to train artificial intelligence models of embryogenesis, with the long-term goal of building a virtual embryo, a predictive computational model capable of forecasting developmental outcomes. Such a model would allow scientists to simulate how perturbations, from genetic mutations to environmental insults, might alter the trajectory of development, opening a new frontier in which mammalian embryogenesis can be studied computationally as well as experimentally.

There is also a humbling lesson embedded in the achievement, one that Weissman draws directly from the history of the roundworm map. When the C. elegans lineage was completed in the 1980s, it led to biological discoveries that no one could have anticipated at the time, precisely because understanding a process and its underlying molecular mechanisms generates questions no one had yet thought to ask. Weissman describes the coming wave of insights from the mouse lineage maps as a source of unknown unknowns, unexpected findings that will emerge simply from having the map in hand. Forty years after a transparent worm gave biology its first complete cellular family tree, two independent teams have brought that same power to a mammal, and the full consequences for understanding development, disease, and the origins of complex tissues are only beginning to come into view.

Subject of Research: Cell lineage tracing in mammalian embryonic development using DNA recording technologies

Article Title: Mapping how a single cell becomes an entire mouse

Article References: Mapping how a single cell becomes an entire mouse. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cell lineage, mouse development, prime editing, PEtracer, DNA Typewriter, embryogenesis, single-cell sequencing, HHMI, Jonathan Weissman, Jay Shendure, developmental biology, virtual embryo

The core idea behind multiplex genome editing is deceptively simple. Where early genome editing tools such as zinc finger nucleases and transcription activator-like effector nucleases, known as ZFNs and TALENs, required a new engineered protein for every DNA target, CRISPR-based systems use small guide RNAs that can be reprogrammed cheaply and quickly. Multiplexing takes this a step further by deploying two or more guide RNAs simultaneously, allowing researchers to edit multiple loci in a single experiment, sometimes down to the single-nucleotide level. Because of this superior precision and feasibility, the authors note, CRISPR-MGE has largely displaced TALENs and ZFNs in plant laboratories worldwide, becoming the default platform for both functional genomics and applied crop improvement.

Delivering many guide RNAs at once posed an early engineering challenge, and the review catalogs the creative solutions that emerged. The most straightforward approach uses individual expression cassettes, with each guide RNA driven by its own promoter, an effective but bulky strategy that becomes unwieldy as target numbers grow. More elegant systems exploit the cell’s own machinery. The endogenous tRNA-processing system, for example, allows researchers to string multiple guide sequences together in a single synthetic gene, flanked by tRNA sequences that the plant itself cleaves apart to release mature guides. This strategy has been demonstrated in maize, rice, and cabbage, among other species. Alternative approaches borrow from bacterial immunity and RNA biology: the CRISPR-associated endoribonuclease Csy4 can process a polycistronic transcript into individual guide RNAs, while self-cleaving ribozymes, first characterized as simple RNA enzymes in the late 1980s, can be placed around guide sequences to achieve the same result.

Beyond these foundational strategies, the review highlights newer advances that have refined multiplex editing into what the authors describe as a powerful, efficient, and robust toolkit. The Cas12a enzyme, formerly known as Cpf1, has proven especially valuable because it processes its own CRISPR RNA arrays, naturally lending itself to multiplexing while recognizing a different protospacer-adjacent motif than Cas9 and thereby expanding the range of editable genomic sites. Engineered Cas12a variants with relaxed PAM requirements and temperature tolerance have extended editing into rice, maize, and tomato under conditions where earlier systems faltered. At the same time, ultra-multiplexing platforms now permit the simultaneous targeting of dozens of loci, and orthogonal systems such as CRISPR-Combo allow genome editing and transcriptional activation to proceed in parallel within the same cell, a capability demonstrated in tomato and other species.

Perhaps the most consequential shift described in the review is the move toward transgene-free editing. Conventional CRISPR experiments introduce DNA constructs that integrate into the plant genome, leaving behind foreign sequences that complicate regulation and public acceptance. DNA-free alternatives circumvent this problem entirely. Preassembled Cas9 ribonucleoproteins, complexes of purified protein and guide RNA, can be delivered into plant cells by PEG-mediated transfection of protoplasts, lipofection, particle bombardment, or cationic lipid nanoparticles, producing edits that are inherited while the editing machinery itself is rapidly degraded and never integrated. The review cites successful DNA-free editing in potato, maize, canola, soybean, citrus, carrot, and tomato, including the generation of transgene-free canker-resistant sweet orange using Cas12a ribonucleoproteins. Virus-based guide RNA delivery systems offer another route, with vectors derived from potato virus X and other plant viruses shuttling guide RNAs through the plant to generate heritable edits without stable transgene integration.

Why does multiplexing matter so much for stress biology? The answer lies in the architecture of plant stress responses. Transcription factors, the DNA-binding proteins that switch suites of target genes on or off, sit at the hubs of regulatory networks that coordinate a plant’s reaction to abiotic stresses such as drought, salinity, cold, and heat, as well as biotic attacks by pathogens and pests. These networks are notoriously redundant and interconnected: single-gene knockouts often produce subtle or no phenotypes because paralogs and parallel pathways compensate. Multiplex editing cuts through this redundancy by disabling entire gene families or combinations of regulators at once, revealing the true structure of the network. The review emphasizes that this capacity makes CRISPR-MGE ideal for elucidating the function of transcription factors, the key molecular players regulating diverse plant responses, especially within stress pathways.

The empirical record assembled in the review illustrates the point across crops and stress types. In rice, knockout of the OsbHLH024 transcription factor improved salt stress resistance, while editing of NAC-family members such as OsNAC15 and OsNAC45 has illuminated their roles in drought, salt, and abscisic acid responses. In tomato, CRISPR-Cas9 mutagenesis of SlNPR1 reduced drought tolerance, confirming its positive regulatory role, while disruption of SlCBF1 diminished chilling tolerance and loss of SlMYC2 compromised methyl jasmonate-induced fruit resistance to the gray mold pathogen Botrytis cinerea. In wheat, simultaneous editing of the three homoeoalleles of TaEDR1 enhanced powdery mildew resistance, a landmark demonstration of why polyploid crops demand multiplex approaches, since useful traits often require hitting all redundant copies at once. Multiplex editing of BnWRKY11 and BnWRKY70 in oilseed rape, and of stress-linked regulators in poplar and grapevine, round out a picture of a technology operating across the plant kingdom.

The toolkit’s reach extends beyond simple knockouts. Multiplex platforms now support base editing, which converts individual DNA letters without cutting both strands, and prime editing, which can install precise sequence changes; both have been deployed in multiplex form in rice, wheat, and maize for agronomically important genes. Nuclease-dead Cas9 fused to activation or repression domains, such as the VP64 activator or the SRAX repressor domain, enables transcriptional regulation of target genes without altering their sequence, and epigenome editing fusions, such as a histone acetyltransferase tethered by dCas9, have improved drought tolerance in Arabidopsis. Metabolic engineering applications, from boosting gamma-aminobutyric acid and lycopene in tomato to raising carotenoid and isoflavone levels in rice and soybean, demonstrate that multiplex editing can reconfigure entire biosynthetic pathways, the same logic needed to tune stress-responsive hormone and antioxidant networks.

The review also confronts the practical bottlenecks that still separate laboratory success from farmers’ fields. Plant regeneration remains a limiting step for many species and genotypes, though morphogenic regulators such as GRF-GIF chimeric proteins and growth-regulating factors are boosting transformation efficiency in crops like sorghum and wheat. Quantifying editing outcomes has grown more rigorous with droplet digital PCR and microfluidic chip-based digital PCR, which allow precise measurement of edit frequencies, an important safeguard given that off-target mutations and variable on-target activity remain persistent concerns. Regulatory landscapes, which differ between process-based and product-based frameworks across jurisdictions, will shape how quickly edited stress-tolerant varieties reach the market, and the authors implicitly position transgene-free methods as a way to ease that transition.

Taken together, the review delivers a clear message to the plant science community: advanced multiplex genome editing is no longer an experimental luxury but the central instrument for decoding and redesigning stress-responsive transcription factor networks. As the authors argue, deploying these tools for the functional characterization of stress-responsive transcription factors holds genuine potential to accelerate crop improvement at a moment when rising salinity, erratic rainfall, and emerging pathogens threaten harvests across South Asia and beyond. The convergence of ultra-multiplexing, orthogonal regulation, DNA-free delivery, and precision base and prime editing means that researchers can now ask, and answer, questions about genetic redundancy and network logic that were unanswerable only a few years ago. The next generation of climate-resilient crops, the review suggests, will be written not one gene at a time, but in whole regulatory paragraphs.

Subject of Research: CRISPR multiplex genome editing of stress-responsive transcription factor networks for crop improvement

Article Title: Advances in CRISPR multiplex gene editing to map and modify stress-responsive transcription factor networks for crop improvement

Article References: Sharma, N. N., Kumari, A., Vashisht, I., & Sharma, M. K. (2026). Advances in CRISPR multiplex gene editing to map and modify stress-responsive transcription factor networks for crop improvement. Plant Cell Reports, 45(9), Article 277. https://doi.org/10.1007/s00299-026-03956-w

Image Credits: AI Generated

DOI: 10.1007/s00299-026-03956-w

Keywords: CRISPR, multiplex genome editing, transcription factors, stress response, crop improvement, Cas12a, base editing, prime editing, transgene-free editing, drought tolerance, salt tolerance, plant biotechnology

The limitations of conventional breeding are stark. Hybridization-based pyramiding of favorable genes typically requires ten to fifteen years per cycle, and screening efficiency is low. Worse, genetic linkage often ties desirable genes to undesirable neighbors on the same chromosome, producing genetic drag that breeders cannot easily escape. Because recombination during crossing is random, traditional methods cannot target multi-gene networks or create rare combinations of favorable alleles that simply do not exist in nature. Crop yield itself is not governed by a single gene but emerges from synergistic interactions among growth, disease resistance, pest resistance and stress tolerance networks, while quality traits involve nutrition, taste and appearance simultaneously. Single-trait improvement, the review concludes, leaves an inherent gap between what breeding can deliver and what modern agriculture needs.

Multiplex genome editing closes that gap by exploiting the core mechanics of the CRISPR/Cas system. A single guide RNA forms a ribonucleoprotein complex with a Cas endonuclease, recognizes target double-stranded DNA through base pairing and a protospacer adjacent motif, and induces a site-specific double-strand break. Cellular repair then proceeds through error-prone non-homologous end joining, whose small insertions and deletions can knock out a gene by frameshifting its reading frame, or through template-directed homology-directed repair. The decisive advantage of MGE is that a single vector, delivered in one transformation, can carry guides for many loci at once, coordinating expression across pathways without touching unrelated genes.

The technology’s power is clearest in cases where single-gene edits fail. Genetic redundancy means that mutating one member of a gene family often produces no visible phenotype because homologous genes compensate. In wheat, broad-spectrum resistance to powdery mildew was achieved only by simultaneously mutating all three homoeoalleles of the TaMLO gene family across the A, B and D genomes; plants with a single copy knocked out remained susceptible. The same principle holds in Arabidopsis, where the AtMLO2/6/12 triple mutant shows markedly enhanced pathogen resistance. The review traces the field’s milestones from early two-guide experiments in Arabidopsis and rice, through the tRNA-sgRNA tandem arrays that let one transcript yield many mature guides, to the current record of thirteen target sites edited simultaneously in rice.

Three co-expression architectures dominate the toolkit. The Multi-Transcriptional Unit system drives each sgRNA with its own RNA polymerase III promoter, offering modular control but risking plasmid recombination from repeated promoter sequences and producing bulky vectors. The Twin-Transcriptional Unit system separates Cas9 and sgRNA expression, processing a single polycistronic precursor with tRNA, Csy4 ribozyme or Hammerhead elements; the tRNA strategy, which hijacks the plant’s own RNase P and RNase Z machinery, achieved over fifty percent simultaneous mutation of three genes in rice and supports a modular toolkit for up to eight targets. The Single Transcriptional Unit system fuses Cas9 and sgRNAs into one compact transcript, ideal for species like soybean that tolerate vector redundancy poorly. Species choice matters: monocots such as rice and wheat favor MCTU and TCTU designs, while dicots often require species-specific Pol II promoters and careful control of tandem target numbers.

Applied outcomes span every major breeding goal. In disease resistance, simultaneous targeting of the Bsr-d1, Pi21 and ERF922 genes produced rice varieties resistant to both blast and bacterial blight, with field durability two to three years longer than single-gene lines, because pathogens must overcome multiple infection barriers at once. In abiotic stress, editing three genes governing root development, grain shape and cold response yielded rice that lost only 3.2 percent of yield under cold stress, compared with fifteen to twenty percent losses in conventional cold-tolerant varieties. Tomato plants edited at the HyPRP1 gene gained over forty percent salt tolerance plus cross-resistance to drought and cold. Yield work has been equally striking: editing GS3, TGW3 and GW8 produced high-yielding hybrid rice with slender grains, while combining eight sgRNAs against cytochrome P450 homologs and the BADH2 gene boosted yield and endowed grains with a fragrant aroma.

Quality improvement may be the most commercially compelling frontier. In soybean, knocking out the GmFAD2-1A and GmFAD2-1B desaturase genes created high-oleic-acid oil with better oxidative stability, and stacking those edits with lipoxygenase knockouts removed the beany flavor that limits soy products. Combining two multiplex-edited soybean varieties allowed researchers to tune protein functionality, including emulsifying activity, gelation and solubility, by editing storage protein genes such as Glycinin and beta-Conglycinin. In tomato, simultaneous editing of the PSY1, MYB12 and SGR1 genes recolored fruit and improved nutrition, while triple knockout of LCY, SGR1 and BLC1 blocked carotenoid branch metabolism and raised lycopene accumulation fivefold. Wheat edited across eight gliadin genes points toward hypoimmunogenic bread, and knocking out three soybean lipoxygenase genes eliminated off-flavors.

Perhaps the most visionary application is de novo domestication. Because centuries of artificial selection narrowed the genetic base of crops and discarded valuable stress-resistance traits found in wild relatives, MGE offers a shortcut: edit domestication genes directly in wild germplasm. Researchers established the first de novo domestication system for wild allotetraploid rice, Oryza alta, editing homologs controlling seed shattering, awn length, plant height and grain traits. Even more dramatic, the salt-tolerant landrace Sea Rice 86 was improved by synchronously editing thirteen key agronomic genes in a single transformation; the resulting homozygous line retained its salt tolerance while gaining improvements in plant height, architecture, grain shape, yield components and photoperiod sensitivity. Wild tomato has likewise been rapidly domesticated with eight sgRNAs targeting six agronomic genes, producing larger fruits and higher lycopene content.

Challenges remain substantial. Gene interactions can be antagonistic as well as synergistic: editing rice grain length, width and number genes together raised yield, but loss of Gn1a overactivated cytokinin signaling, multiplying tillers and undermining lodging resistance, a problem that had to be solved by recombining targets such as Ghd7, DTH8 and OsNAC006. Editing efficiency decays with scale, holding at fifty to seventy percent for three to five genes but dropping below thirty percent beyond eight targets. New tools are responding: Cas12a uses short crRNAs that cut sequence redundancy by more than half, processes its own arrays without exogenous enzymes, and engineered variants like Mb3Cas12a now work across relaxed PAM sites and low temperatures. Prime editing, which installs precise changes without double-strand breaks, achieved 28.6 percent dual-site and 7.1 percent quadruple-site efficiency in rice, while an ultra-efficient tomato system reached 87.5 percent single-target precision with multiplex rates matching single edits.

Delivery and design are the next battlegrounds. Agrobacterium transformation and particle bombardment remain mainstream but struggle with large multiplex vectors and recalcitrant species, and both depend on laborious tissue culture. Virus-induced genome editing offers a way out: a Barley stripe mosaic virus system delivering sgRNAs into Cas-expressing wheat reached up to 47.3 percent dual-gene editing in the first generation, with over eighty percent of mutants virus-free by the next, while SYNV vectors can carry the entire CRISPR/Cas machinery in one round. On the design side, machine learning and large language models such as CRISPR-GPT are automating sgRNA selection, and AlphaFold-guided editing has already produced high-oil soybean alleles by predicting which mutations preserve protein structure. The review’s authors frame the trajectory clearly: as efficiency bottlenecks fall and intelligent design matures, multiplex genome editing is propelling crop breeding from experience-dependent craft toward precision engineering of complex, customized traits, a shift with consequences for global food security that are only beginning to unfold.

Subject of Research: CRISPR/Cas-mediated multiplex genome editing for pyramiding multiple agronomic traits in crop breeding

Article Title: Multiplex gene editing drives revolution in crop breeding: overlaid editing of multiple genes and customization of complex traits

Article References: Lin, J., Hazaisi, H., Guan, Y., & Bai, M. (2026). Multiplex gene editing drives revolution in crop breeding: overlaid editing of multiple genes and customization of complex traits. Advanced Biotechnology, 4(1), Article 5. https://doi.org/10.1007/s44307-026-00099-7

Image Credits: AI Generated

DOI: 10.1007/s44307-026-00099-7

Keywords: CRISPR/Cas9, multiplex genome editing, crop breeding, trait pyramiding, Cas12a, prime editing, de novo domestication, rice, soybean, tomato, wheat, virus-induced genome editing

The review begins where the technology itself began: in prokaryotes. CRISPR-Cas systems evolved as adaptive immune defenses in bacteria and archaea, storing fragments of viral DNA in genomic memory banks and using them to recognize and destroy invading genetic material. When researchers realized that this bacterial immune machinery could be reprogrammed with a single guide RNA to target nearly any sequence of interest, the implications were enormous. Early CRISPR-Cas9 experiments demonstrated remarkable efficiency and ease of use compared with earlier genome-editing platforms such as zinc-finger nucleases and transcription activator-like effector nucleases, which required laborious protein engineering for each new target.

Yet the honeymoon was short-lived. As clinical ambitions grew, so did concern over off-target effects, the unwanted edits that occur when the Cas9 nuclease acts at sites that only partially match the guide RNA. Variable editing outcomes, unpredictable insertions and deletions at the target site, and the risk of large genomic rearrangements all limited the technology’s broader application to human therapy. The review emphasizes that these technical shortcomings, alongside delivery inefficiencies that make it difficult to get editing machinery into the right cells in the right tissues, remain among the field’s most persistent challenges even as the toolkit has grown far more sophisticated.

The evolution from scissors to editors is best embodied by the rise of base editing and prime editing. Rather than relying on double-strand breaks and the cell’s error-prone repair pathways, these newer approaches chemically convert individual DNA letters or write short new sequences with minimal collateral damage. The review highlights work demonstrating that prime editing can correct oncogenic KRAS variants without the constraints imposed by traditional CRISPR-Cas9 workflows, and that CRISPR-based strategies have achieved efficient correction of both KRAS and TP53 mutations, two of the most frequently mutated genes in human cancer. Such results illustrate the conceptual shift: the goal is no longer simply to disrupt a gene but to rewrite it precisely, restoring normal function rather than merely silencing a faulty instruction.

Cancer therapy has emerged as one of the most active arenas for these refined tools. The review surveys how CRISPR-Cas9 library screening has accelerated anti-cancer drug discovery by systematically identifying genes that tumors depend on, and how ex vivo editing of immune cells is reshaping immunotherapy. Chimeric antigen receptor T cells engineered with CRISPR have shown that targeting the CAR construct to a defined genomic locus, such as the TRAC locus, can enhance tumor rejection compared with randomly integrated vectors. Editing of natural killer cells and T cells from human donors is being pursued for cancer immunotherapy, and strategies to improve CAR-T cell persistence through CRISPR-mediated knockout of exhaustion-related pathways are advancing through preclinical and clinical pipelines.

Beyond cancer, the review catalogs applications across viral disease, autoimmune conditions and inherited disorders. CRISPR-based approaches are being developed to engineer resistance to viruses, with HIV-1/AIDS therapy representing a prominent example in which editing aims to remove or disable viral genomes integrated into host DNA. Diagnostic platforms derived from CRISPR nucleases, including SHERLOCK and DETECTR, exploit the sequence-specific recognition of Cas enzymes to detect viral nucleic acids with high sensitivity, offering rapid tools for emerging infectious diseases. In autoimmune disease research, genome editing is being used to dissect and potentially correct the immune dysregulation that underlies conditions such as lupus and rheumatoid arthritis, pointing toward a future in which the immune system itself can be retuned at the genetic level.

None of these therapeutic visions can be realized without solving the delivery problem, and the review devotes substantial attention to the technologies that ferry editing machinery into cells. Viral vectors, particularly adeno-associated virus and lentiviral vectors, offer efficient gene transfer but raise questions about payload capacity, insertional risks and immune responses. Non-viral alternatives include physical methods such as electroporation and microinjection, lipid nanoparticles and solid lipid nanoparticles, cell-penetrating peptides, DNA nanocarriers and extracellular vesicles. Nanotechnology-based delivery of CRISPR components for cancer treatment is a particularly active frontier, with gold nanoparticles and other platforms being evaluated for biocompatibility and cytotoxicity under evolving regulatory frameworks. The choice of delivery vehicle, the review makes clear, often determines whether an elegant editing strategy can ever reach the clinic.

Even when editing succeeds, the human body may object. Immunogenicity of the bacterial Cas9 protein is a recognized concern, since many people carry pre-existing antibodies and T cells reactive to common Cas variants from environmental exposure to the microbes that harbor them. The review also confronts the ethical dimensions that shadow every advance in the field. The prospect of human germline and heritable genome editing has prompted a global policy debate about where the lines should be drawn, and ethicists have argued that the moral considerations raised by such a powerful tool demand attention to accessibility, consent and the long-term consequences of permanent genomic change. Who will be able to afford these therapies, and how societies will govern their use, remain unresolved questions that the technical community cannot answer alone.

What emerges from the review is a portrait of a technology on a clear trajectory. Engineered Cas variants, such as PAM-flexible chimeric Cas9 proteins that relax the sequence constraints on where editing can occur, are expanding the addressable space of the genome. High-fidelity nucleases reduce off-target activity, base and prime editors increase the precision of the intended change, and improved delivery systems broaden the range of treatable tissues. Together these refinements position CRISPR as an increasingly precise platform for both fundamental research and therapeutic use, supporting targeted therapies for genetic disorders in ways that the original scissor paradigm could never achieve. The authors, based at the University of Science and Culture and the Royan Institute in Tehran, frame this progression not as a completed project but as an ongoing evolution toward greater specificity, safety and predictability.

The clinical momentum is already visible. Approved CRISPR-based therapies for hemoglobin disorders have demonstrated that genome editing can deliver durable benefit in patients, and dozens of trials are testing edited cell therapies, in vivo editing and CRISPR-enabled diagnostics across a widening spectrum of disease. The remaining obstacles, off-target editing, delivery inefficiency, immune reactions and equitable access, are formidable but no longer conceptual; they are engineering and policy problems with active research programs attached to each. As Rahbari, Lohrasbi and Amiri-Yekta conclude, the story of therapeutic genome editing is one of steady refinement, in which the crude power of the original molecular scissors is being progressively replaced by the controlled, predictable hand of a true genome editor. The precision revolution they describe is redefining what medicine can attempt at the level of DNA itself, and the pace of that redefinition shows no sign of slowing.

Subject of Research: The evolution of CRISPR-based genome editing from early nuclease cutting tools toward precise therapeutic platforms for genetic disease

Article Title: From scissors to editors: how the evolution of precision is redefining therapeutic genome editing

Article References: Rahbari, M., Lohrasbi, R., & Amiri-Yekta, A. (2026). From scissors to editors: how the evolution of precision is redefining therapeutic genome editing. Molecular Genetics and Genomics, 301(1), Article 193. https://doi.org/10.1007/s00438-026-02467-3

Image Credits: AI Generated

DOI: 10.1007/s00438-026-02467-3

Keywords: CRISPR-Cas9, genome editing, gene therapy, base editing, prime editing, off-target effects, cancer immunotherapy, CAR-T cells, viral vectors, nanoparticle delivery, precision medicine, genetic disorders

Prime editing, introduced by David Liu’s group at the Broad Institute in 2019, combined a catalytically impaired Cas9 nickase with an engineered reverse transcriptase and a guide RNA that carries both the targeting information and the template for the desired edit. The system writes new sequence directly into the genome without making a full double-strand break, avoiding the chaotic repair outcomes that plague conventional CRISPR-Cas9 cutting. Yet prime editing has always faced a ceiling: the efficiency and precision of the approach decline sharply as the requested edit grows larger. Insertions of more than a few dozen base pairs become unreliable, and integrating entire genes or rearranging chromosome segments has remained largely out of reach.

Prime assembly tackles that ceiling by reconceiving the edit as a stepwise construction process rather than a single copying event. Instead of forcing the reverse transcriptase to polymerize a long, unwieldy DNA tract in one continuous reaction, the system orchestrates a series of coordinated sub-edits, each installing a defined fragment at the target locus. Because each fragment is short enough to be written with high fidelity, the assembled product can extend to kilobase scale while maintaining the sequence accuracy that defines prime editing. The design encodes overlapping junctions within the delivered template RNAs so that successive fragments anneal to one another and to the genomic target, stitching the pieces into a contiguous, correctly ordered insert.

The molecular choreography relies on a redesigned editing complex. The researchers report engineering the prime editor apparatus and its guide RNA architecture so that multiple template modules can be loaded and processed in a defined sequence at the same target site. Timing and polarity matter enormously in genome writing: a fragment installed out of order, or in the wrong orientation, would leave behind scars or truncate the intended product. The prime assembly system addresses this by controlling the order in which template segments are reverse-transcribed and by using nicking patterns that favor progressive extension of the nascent strand. In effect, the genome itself becomes the scaffold on which the new sequence is assembled, and the cell’s own repair machinery seals the final junctions.

What distinguishes the work most sharply from earlier large-insert methods is the degree of control over rearrangement. Transposon-based delivery systems can move large cargoes but do so at their own preferred genomic sites, and double-strand-break-dependent methods such as CRISPR paired with homologous recombination or non-homologous end joining frequently generate a messy mixture of deletions, inversions, and random integrations. Prime assembly, by contrast, specifies both the landing site and the structure of the rearrangement. The paper demonstrates targeted integration of sizable genetic payloads, precise excision of unwanted segments, and programmable reorganization of DNA segments within a locus, all without introducing a double-strand break at any point in the procedure.

The technical benchmarks reported in the study emphasize both efficiency and purity. Across the demonstrated edit classes, the authors describe insertion products that are predominantly exact, with detectable byproducts reduced relative to break-dependent alternatives. Sequence-level analysis of the assembled products shows the expected junction architecture, an important indicator that the overlapping-fragment design behaves as intended rather than relying on stochastic recombination. Editing outcomes were profiled at the DNA level with deep sequencing and, for the larger rearrangements, with long-read sequencing capable of confirming the structure of multi-kilobase changes end to end, a level of verification that smaller-scale editing studies rarely require.

The implications for disease research are considerable. A large fraction of pathogenic mutations are not simple point substitutions. Thousands of known genetic disorders arise from deletions, duplications, insertions of mobile elements, or larger structural changes that conventional single-nucleotide editors cannot address. Gene-addition therapies using viral vectors can deliver a working copy of a gene, but they insert it at a semi-random safe-harbor location rather than restoring the native locus, losing native regulation and occasionally provoking insertional complications. Prime assembly offers a route to writing a functional gene back into its endogenous position, complete with its own regulatory context, or to rebuilding a damaged locus from the bottom up.

Synthetic genome engineering stands to benefit even more directly. Building entire chromosomes and synthetic genomes has so far depended on laborious cycles of homologous recombination in yeast or on assembly in vitro followed by transplantation, approaches that are slow and species-limited. A method that can integrate large designed sequences at user-chosen genomic addresses in mammalian or other difficult cells would compress that workflow dramatically. The authors’ demonstration of programmable rearrangement suggests a longer-term vision in which genome architecture itself, not merely gene sequence, becomes an editable design parameter, allowing researchers to test in weeks what once took years of strain construction.

As with every genome-editing advance, the distance between a demonstration in cultured cells and a therapeutic reality is substantial. Delivery remains the field’s perennial bottleneck: prime editors are large multi-component systems, and a prime assembly platform that carries multi-part template cargoes is larger still, making efficient in vivo delivery a formidable engineering problem in its own right. Off-target activity, immunogenicity of the bacterial-derived editor proteins, and the long-term stability of large engineered loci will all need rigorous assessment. The authors and the field more broadly will also need to establish how the method performs in primary cells, tissues, and whole organisms, where chromatin context and cell-cycle state strongly influence repair outcomes.

Even with those caveats, prime assembly represents a conceptual milestone in the transition of genome editing from correction to construction. The first decade of CRISPR made cutting routine; the second made precise rewriting of individual letters increasingly reliable. Prime assembly points toward a third phase in which geneticists can move, add, and reorganize whole stretches of the genome with the same programmability that made base editing famous. For patients with structural variants that no current therapy can touch, and for engineers attempting to build genomes to specification, the ability to assemble DNA in place, fragment by fragment, at the exact location of choice, may prove to be one of the more consequential ideas to emerge from the genome-writing field in years.

Subject of Research: Prime assembly genome editing for targeted DNA integration and rearrangement

Article Title: Targeted genomic integration and rearrangement using prime assembly

Article References: Levesque, S., Kawashima, N., Hwang, G.-H., Zeng, J., Toskov, V., Barry, T., Mannherz, W., Homfeldt, L., Becerra, B., Schoonenberg, V. A. C., Pinello, L., Agarwal, S., & Bauer, D. E. (2026). Targeted genomic integration and rearrangement using prime assembly. Nature. https://doi.org/10.1038/s41586-026-11024-2

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11024-2

Keywords: prime assembly, prime editing, genome editing, gene writing, CRISPR, reverse transcriptase, DNA integration, structural variants, synthetic genomics, gene therapy, molecular biology, biotechnology

Base editors represent one of the most elegant refinements of the original CRISPR-Cas9 concept. Rather than cutting both strands of DNA and relying on the cell’s error-prone repair machinery—a process that generates random insertions and deletions—base editors fuse a catalytically impaired Cas nickase to a deaminase enzyme that chemically converts one nucleobase into another. Cytosine base editors, the class at the center of the new work, convert C-G base pairs into T-A pairs without creating double-strand breaks or requiring a donor DNA template. This is a critical advantage given that more than half of known human hereditary diseases are caused by single point mutations, and that precision breeding in agriculture likewise demands exact nucleotide changes rather than gene knockouts.

The Achilles’ heel of conventional cytosine base editors has been precision. Most editors operate across a wide activity window spanning roughly four to seventeen nucleotides, meaning they can alter not just the intended target cytosine but also nearby ‘bystander’ cytosines. That is a serious problem in a clinical context: many disease-associated alleles, including those in the HBB locus linked to beta-thalassemia, the APOE4 gene associated with Alzheimer’s disease, and the TYR locus involved in oculocutaneous albinism, contain multiple cytosines within a typical editing window. Even synonymous substitutions, which do not change the encoded amino acid, have been shown to exert strong non-neutral effects, underscoring the risk of any unintended edit.

The research team, building on their earlier development of high-precision editors based on CDA1, a deaminase from the sea lamprey, tackled two intertwined limitations: targeting scope and efficiency. Previous work had shown that trimming thirteen to twenty amino acids from the C-terminus of CDA1 restricts the editing window so that the editor overwhelmingly modifies a single cytosine at position C-18 relative to the PAM sequence. But those editors still required a guanine within the PAM, leaving many genomic sites inaccessible. To eliminate this constraint, the researchers replaced the standard Cas9 nickase with nSpRY, an engineered variant that tolerates nearly any three-nucleotide sequence as a PAM, effectively enabling editing at almost any genomic location.

A series of experiments in yeast demonstrated that the combination worked, and in a surprisingly beneficial way. Seven editor variants were built, pairing nSpRY with full-length or truncated CDA1, and tested on twelve target sites lacking NGG PAM motifs, including demanding stretches of consecutive cytidines. The truncated variants produced editing windows of only one to two nucleotides, centered on C-18, and frequently converted the target cytosine two to three times more efficiently than its nearest neighbor. Even more strikingly, the truncated SpRY editors outperformed the full-length editor at position C-18 itself—by up to 6.11-fold at certain sites. Deep sequencing of the sgRNA expression plasmids revealed why: the full-length editor engaged in broad ‘self-editing’ of the guide RNA spacer, introducing multiple mismatches that cripple CRISPR targeting, whereas the truncated editor confined self-editing mostly to a single position, preserving a larger pool of functional guides.

The team then distilled their findings into a straightforward four-step design workflow that allows researchers to precisely edit any user-chosen cytidine in a genome: identify the target cytosine, design a guide RNA that places it at position -18, select the appropriate editor based on the PAM context—standard nCas9 editors for NGG PAMs, Cas9-NG or SpG editors for NGH PAMs, and SpRY editors for everything else—and pick the optimal CDA1 truncation. Validating the approach, the researchers targeted each of three consecutive cytidines at a randomly chosen yeast locus. Their best editor, CDA1Δ194-SpRY-BE3, converted the intended cytosine 1.05- to 7.41-fold more efficiently than its bystander neighbors, with single-target products making up 41.60 to 63.65 percent of all edited reads. The full-length control editors, by contrast, produced fewer than 8.7 percent of the desired single-target products, instead yielding doubly and triply edited molecules.

With precision and targeting scope secured, the remaining challenge was efficiency, which is often compromised in PAM-flexible Cas9 variants. The researchers systematically screened fifteen DNA-interacting proteins spanning four functional classes—transcription activators, chromatin-associated factors, pioneer transcription factors, and bacterial DNA-bending peptides—fusing each to the N-terminus of their best editor. Most fusions reduced activity, but two stood out: HMGN1, a nucleosome-binding chromatin protein, and VP64, a potent viral transcriptional activator domain. Individually they delivered modest gains, averaging 1.17-fold and 1.42-fold respectively. But combining both factors produced a dramatic synergistic effect: across thirty-six tested target sites, the dual fusion boosted average editing efficiency 4.24-fold, with improvements observed at every site examined. In multiplex editing experiments using two guide RNAs simultaneously, the fusion editor achieved 6.86-fold and 2.31-fold efficiency increases at two loci while retaining its narrow editing window and generating 40.61 percent and 26.12 percent C-18-only products, compared with just 3.2 and 7.98 percent for the control editor. The strategy also generalized: fusing HMGN1 and VP64 to an rAPOBEC1-based SpRY editor yielded an average 2.47-fold efficiency gain across eleven loci.

Safety analyses confirmed that the enhanced editors did not sacrifice specificity. Whole-genome sequencing of edited yeast showed that truncated-CDA1 editors produced fewer genome-wide single-nucleotide variants than full-length constructs, and although VP64 caused a slight uptick in SNVs—likely because the activator domain can expose single-stranded DNA by altering local transcription—the fusion editors remained well below the off-target levels of canonical editors. Off-target RNA editing was likewise negligible for truncated variants, and targeted sequencing of predicted guide-dependent off-target sites showed frequencies comparable to controls. The truncated CDA1Δ190 variant in particular displayed transition levels nearly indistinguishable from unedited controls.

Crucially, the platform extended beyond yeast. In rice cells, the optimized truncated editor improved editing efficiency at eighteen of twenty endogenous target sites relative to full-length controls, with gains ranging from 1.32-fold to an extraordinary 4,617.95-fold and a maximum efficiency of 61.09 percent. Adding the HMGN1-VP64 fusion pushed performance further still, with improvements of up to 5,938.93-fold and a peak efficiency of 78.57 percent. In a direct head-to-head comparison with ePPE, a plant-optimized prime editor, at seven non-NGG target sites, the fusion base editor outperformed prime editing at six of seven sites, achieving efficiencies 2.27- to 28.61-fold higher and averaging 18.53 percent versus 5.31 percent for ePPE, albeit with slightly more bystander editing.

The authors position their enhanced base editors and prime editors as complementary tools rather than competitors: prime editors excel at installing diverse edit types with high product purity, while the new high-precision base editors offer unmatched efficiency for C-to-T transitions at previously unreachable genomic sites. Remaining challenges include the lower absolute efficiency at NYN PAMs, where SpRY’s intrinsic DNA-binding affinity appears rate-limiting, suggesting that next-generation variants such as the chimeric SpRYc could push the system even further. For now, the work delivers a versatile toolkit—one that pairs surgical precision with near-universal targeting reach and robust efficiency across yeast and rice—whose implications extend from functional genomics and precision crop breeding toward the long-term goal of safely correcting the point mutations that underlie much of human genetic disease.

Subject of Research: Engineering synergistic HMGN1 and VP64 fusions with truncated CDA1 and PAM-flexible SpRY Cas9 for high-precision cytosine base editing

Article Title: Synergistic HMGN1 and VP64 Fusions Potentiate High‐Precision and PAM‐Flexible Base Editing

Article References: Luo, X., Qu, Y., Ye, Z., Li, Z., Zhang, Y., Luo, L., Li, S., Zhao, W., Wang, M., Bock, R., Wan, J., & Tan, J. (2026). Synergistic HMGN1 and VP64 Fusions Potentiate High‐Precision and PAM‐Flexible Base Editing. Advanced Science, 13(50), Article e76047. https://doi.org/10.1002/advs.76047

Image Credits: AI Generated

DOI: 10.1002/advs.76047

Keywords: base editing, CRISPR-Cas9, SpRY, CDA1 deaminase, HMGN1, VP64, PAM-flexible targeting, bystander editing, cytosine deamination, rice genome editing, prime editing, gene therapy

The work addresses a gap that has shaped the trajectory of genome engineering for more than a decade. Since the advent of programmable nucleases, researchers have been able to direct double-strand breaks to almost any chosen sequence, and cellular repair machinery can sometimes stitch in a new DNA cassette at the break site. But that approach leans on the cell’s own repair pathways, which are error-prone, unpredictable and often disabling to the very sequences scientists want to insert. Broken DNA is dangerous DNA, and cells treat integration events as injuries to be patched rather than as opportunities for precise reconstruction.

Prime editing, first described in 2019, took a fundamentally different route. Rather than cutting both strands of the DNA double helix, a prime editor pairs a Cas9 nickase — an engineered enzyme that cuts only one strand — with an engineered reverse transcriptase. The editing instructions are carried on a prime editing guide RNA, or pegRNA, which both locates the target site and encodes the new genetic information the reverse transcriptase should write into the nicked strand. Because the process avoids double-strand breaks and does not require an additional donor DNA template supplied in bulk, prime editing has proven remarkably clean for small substitutions, insertions and deletions.

Where prime editing has historically faltered, however, is scale. The reverse transcriptase copies a sequence encoded within the pegRNA itself, and practical constraints on RNA length, delivery and synthesis efficiency have limited the size of the DNA payload that a single prime-editing event can install. For applications in which a functional gene, a large regulatory element or a multi-kilobase cassette must be placed at a defined genomic address, the technology’s ceiling has been a persistent frustration. Complementary systems — including CRISPR-associated transposases and integrase-based platforms — can move larger cargoes, but they typically bring their own constraints on target-site selection, orientation and cargo compatibility.

The new study, led by researchers working at the interface of protein engineering and genome technology, tackles the size problem by rethinking how the donor DNA participates in the reaction. In the reported strategy, termed donor-directed annealing, the genetic cargo is carried on a separate donor molecule rather than being encoded within the pegRNA. The prime editor still performs its characteristic task of opening the target site and synthesizing an exposed stretch of new DNA on the nicked strand, but that newly synthesized sequence is designed to serve as a molecular landing pad. Once exposed, it is complementary to sequences at the end of the donor fragment, and the two single-stranded regions find each other and anneal, drawing the donor cargo into the editing site.

The elegance of the design lies in what happens next. Cellular DNA repair enzymes process the annealed intermediate, ligating the donor fragment into the genome through the natural resolution of the flap-like structure that the prime editor has created. Because the specificity of the event is dictated by sequence complementarity between the editor-generated overhang and the donor terminus, the cell is never asked to recognize a double-strand break or to improvise an end-joining reaction. The authors report that this mechanism allows fragments substantially larger than the payloads accessible to conventional prime editing to be incorporated at defined loci, with precision determined largely by the programmed overlap rather than by stochastic cellular repair.

From a biochemical standpoint, donor-directed annealing converts what has been an intramolecular copying reaction into a hybridization-guided assembly step. Conventional prime editing is, in essence, a controlled form of DNA synthesis: the pegRNA templates every base that the reverse transcriptase installs. The new method retains that templated synthesis for a short anchoring sequence but delegates the bulk of the payload to a separate donor, which can be produced synthetically or by standard cloning at lengths far beyond what a pegRNA can encode. The trade-off is that the donor and the pegRNA must be co-delivered and their sequences coordinated, but the payoff is a system in which cargo size is no longer bound to the physical limits of the guide RNA.

The practical implications extend across both research and therapeutic arenas. In basic biology, the ability to drop large regulatory modules, reporter constructs or engineered gene circuits into precise genomic contexts would simplify experiments that currently require laborious screening of random integration events. In medicine, many inherited disorders are caused by mutations in genes that are too large, too structurally complex or too mutationally diverse to be addressed base by base. Delivering a corrected copy of a gene, or a functional cDNA, into its native locus under the control of endogenous regulatory elements — rather than scattering it randomly through the genome as viral vector gene therapy does — remains the aspirational gold standard, and integration strategies of this kind are among the most credible paths toward it.

The reported system also speaks to a recurring theme in the genome-editing literature: the value of avoiding double-strand breaks altogether. Studies across multiple cell types have associated double-strand-break-based editing with p53 activation, chromosomal rearrangements and large unintended deletions, concerns that are particularly acute for ex vivo cell therapies and in vivo applications alike. By building integration on a nicking enzyme and sequence-programmed annealing rather than on blunt-ended break repair, the approach aligns with the field’s broader movement toward editing chemistries that leave the genome’s integrity machinery largely undisturbed.

As with any genome-engineering advance, several questions will shape how the technique matures. The efficiency of integration across different genomic loci, cell types and species will need systematic mapping; cargo lengths will have practical ceilings set by delivery vehicles rather than by chemistry; and off-target activity — a concern for any nuclease-fusion system — will require careful characterization at both the sequence and chromosomal level. The study’s authors report encouraging precision at the sites they examined, and the strategy’s dependence on designed sequence complementarity offers a built-in specificity checkpoint that many integration methods lack. Independent replication and optimization in therapeutically relevant primary cells will be the next milestones.

What the work illustrates most clearly is how quickly the conceptual boundaries of genome editing continue to move. In barely a decade, the field has progressed from cutting DNA at chosen addresses, to rewriting individual letters of the genetic code, to contemplating the programmed installation of whole functional modules at will. Donor-directed annealing extends prime editing’s core strengths — precision, minimized DNA damage and programmability — into a size regime that those strengths had not previously reached. If the method’s efficiency and reliability hold up as it is tested more broadly, large-fragment insertion could shift from a heroic, low-yield exercise to a routine operation in the genome engineer’s toolkit, with consequences for drug discovery, synthetic biology and, ultimately, the treatment of diseases that small edits alone cannot fix.

Subject of Research: Precise integration of large DNA fragments into genomic target sites using prime editing with donor-directed annealing

Article Title: Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing

Article References: Jung, H., Jeong, B., Kim, Y.-W., Jung, C., Lee, S., Uhm, H., Kim, H., Oh, Y. E., Park, Y., Lee, Y., Kang, M., Im, H. W., Kim, D., Lee, S., Kim, Y., Choi, K., & Bae, S. (2026). Precise genomic integration of large DNA fragments by donor-directed annealing using prime editing. Nature Biotechnology. https://doi.org/10.1038/s41587-026-03301-2

Image Credits: AI Generated

DOI: 10.1038/s41587-026-03301-2

Keywords: prime editing, genome editing, CRISPR, gene therapy, DNA integration, pegRNA, reverse transcriptase, Cas9 nickase, large DNA fragments, donor-directed annealing, biotechnology, genetic engineering